Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | MARS1 | P56192 | 2/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343294 | 0.92 | MARS1 (0.36) | NOD1DPP7CNR1MARS1RRM1 | |
| SCHEMBL1343485 | 0.87 | HPGD (0.36) | NOD1MARS1ALDH1A1 | |
| SCHEMBL1345418 | 0.86 | HPGD (0.35) | MARS1ALDH1A1 | |
| SCHEMBL1345051 | 0.81 | HPGD (0.32) | MARS1ALDH1A1MAPT | |
| SCHEMBL1345150 | 0.80 | DDAH1 (0.42) | ALDH1A1 | |
| SCHEMBL1345238 | 0.78 | DDAH1 (0.44) | NOD1DPP7ACHE | |
| SCHEMBL4167389 | 0.76 | DPP7 (0.46) | NOD1DPP7ACHERRM1 | |
| SCHEMBL578523 | 0.76 | DPP7 (0.46) | NOD1DPP7ACHERRM1 | |
| SCHEMBL1344938 | 0.76 | SLC1A3 (0.47) | DPP7ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL10727145 | 0.75 | DPP7 (0.45) | NOD1DPP7ACHERRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828109-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL BUSINESS PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8063104-B2 | Guanidine derivatives as inhibitors of DDAH | UCL BUSINESS PLC (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | NOD1 2690/4885DPP7 560/4885CNR1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.